OptiBiotix Health PLC Directorate Change (5854K)
17 December 2018 - 6:01PM
UK Regulatory
TIDMOPTI
RNS Number : 5854K
OptiBiotix Health PLC
17 December 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Directorate Change
Appointment of Managing Director of OptiBiotix's prebiotic
division
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the intended departure of Per Rehne as a
director of OptiBiotix Health plc after working a 3 month notice
period. Per will remain as a director of OptiBiotix's newly formed
subsidiary, ProBiotix Health Limited following his departure from
OptiBiotix. A further announcement will be made in due course.
The Board is pleased to announce the appointment of Frederic
Narbel ("Fred") as Managing Director of OptiBiotix's prebiotic
division containing its SweetBiotix, OptiBiotic and microbiome
modulating technology platforms. Fred will join the OptiBiotix
Board subject to completion of the normal regulatory due
diligence.
Fred has 11 years' experience in medical products and speciality
food ingredients, and is joining OptiBiotix from a position as Vice
President of Sales for Nutrition Solutions at Agropur, a Canadian
dairy company with annualised sales of $6.4 billion (2017), and
8,300 employees. Agropur manufactures and distributes functional
ingredients and has extensive operations across Canada and the
US.
Fred brings extensive experience of selling speciality food
ingredients in international markets and has managed sales teams in
China, the USA, Singapore and Europe. He has a good reputation of
building business-to-business sales through commercial partnerships
and working with manufacturers and distributors to rapidly grow
sales revenues in international markets. Fred comes with a wide
network of contacts in the high value speciality food ingredients
industry and a strong track record of rapidly growing sales.
Fred has a Doctorate in Business Administration, and MBA, and is
multilingual in English, French, Finnish and German. His experience
of speciality food ingredients will help drive the
commercialisation of OptiBiotix's growing pipeline of products
across its SweetBiotix, OptiBiotic and microbiome modulating
technology platforms.
Stephen O'Hara, CEO of OptiBiotix, commented: "Fred's experience
and track record of growing business-to-business sales of
speciality food ingredients to provide differentiated nutritional
solutions brings added commercial and industry specific expertise
to OptiBiotix. His network of contacts provides access to new
international markets which we hope will help drive revenue growth
from OptiBiotix's growing pipeline of products amongst its
SweetBiotix, OptiBiotic and microbiome modulating platforms. This
will add further revenue streams to the growing revenues from
OptiBiotix's LP-LDL and SlimBiome products. This is all part of a
wider strategy of developing multiple revenue streams from both
consumer and pharmaceutical products across all OptiBiotix's
technology platforms.
On behalf of the Board, I would like to thank Per for his hard
work with OptiBiotix and look forward to working with him in his
role as a non-executive director of ProBiotix Health."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty five international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAQZLFFVLFFFBE
(END) Dow Jones Newswires
December 17, 2018 02:01 ET (07:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Jul 2023 to Jul 2024